- Home
- PULM vs NXGL Comparison
PULM vs NXGL Comparison
Compare PULM & NXGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- NXGL
- Stock Information
- Founded
- PULM 2003
- NXGL 1997
- Country
- PULM United States
- NXGL United States
- Employees
- PULM N/A
- NXGL N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- NXGL Medical/Dental Instruments
- Sector
- PULM Health Care
- NXGL Health Care
- Exchange
- PULM Nasdaq
- NXGL Nasdaq
- Market Cap
- PULM 20.5M
- NXGL 18.7M
- IPO Year
- PULM N/A
- NXGL 2021
- Fundamental
- Price
- PULM $4.87
- NXGL $2.22
- Analyst Decision
- PULM
- NXGL
- Analyst Count
- PULM 0
- NXGL 0
- Target Price
- PULM N/A
- NXGL N/A
- AVG Volume (30 Days)
- PULM 11.0K
- NXGL 50.3K
- Earning Date
- PULM 08-06-2025
- NXGL 08-12-2025
- Dividend Yield
- PULM N/A
- NXGL N/A
- EPS Growth
- PULM N/A
- NXGL N/A
- EPS
- PULM N/A
- NXGL N/A
- Revenue
- PULM $369,000.00
- NXGL $11,672,000.00
- Revenue This Year
- PULM N/A
- NXGL $46.60
- Revenue Next Year
- PULM $134.88
- NXGL $47.96
- P/E Ratio
- PULM N/A
- NXGL N/A
- Revenue Growth
- PULM N/A
- NXGL 133.02
- 52 Week Low
- PULM $1.78
- NXGL $2.10
- 52 Week High
- PULM $10.40
- NXGL $5.10
- Technical
- Relative Strength Index (RSI)
- PULM 44.33
- NXGL 41.78
- Support Level
- PULM $4.65
- NXGL $2.18
- Resistance Level
- PULM $5.00
- NXGL $2.59
- Average True Range (ATR)
- PULM 0.16
- NXGL 0.15
- MACD
- PULM 0.06
- NXGL -0.01
- Stochastic Oscillator
- PULM 76.92
- NXGL 9.76
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.